Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

West Pharmaceutical Services, Inc. (WST) had Revenue of $2.89B for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$2.89B
Net Income	$492.70M
Cost of Goods Sold	$1.89B
Gross Profit	$998.50M
Operating Expenses	$2.32B
Operating Income	$569.90M
Non-Operating Income/Expense	$15.60M
Pre-Tax Income	$585.50M
Normalized Pre-Tax Income	$585.50M
Income after Taxes	$478.00M
Income from Continuous Operations	$492.70M
Consolidated Net Income/Loss	$492.70M
Normalized Income after Taxes	$478.00M
EBIT	$569.90M
EBITDA	$725.30M
Weighted-Average Shares Outstanding (Basic)	73.00M
Weighted-Average Shares Outstanding (Diluted)	73.70M
Earnings per Share (EPS) (Basic)	$6.75
Earnings per Share (EPS) (Diluted)	$6.69
Balance Sheet Financials
Current Assets	$1.54B
Property, Plant, and Equipment	$1.58B
Long-Term Assets	$2.11B
Total Assets	$3.64B
Current Liabilities	$550.40M
Long-Term Debt	$202.60M
Long-Term Liabilities	$410.70M
Total Liabilities	$961.10M
Common Equity	$2.68B
Tangible Shareholders Equity	$2.57B
Shareholders Equity	$2.68B
Common Shares Outstanding	72.30M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$653.40M
Cash Flow from Investing Activities	$-378.70M
Cash Flow from Financial Activities	$-622.60M
Beginning Cash	$853.90M
End Cash	$484.60M
Increase/Decrease in Cash	$-369.30M
Stock-Based Compensation	$18.70M
Common Stock Dividends Paid	$-59.10M
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.79
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.07
Debt to Equity Ratio	0.08
Gross Margin	34.51%
Operating Margin	19.70%
EBIT Margin	19.70%
EBITDA Margin	25.07%
Pre-Tax Profit Margin	20.24%
Profit Margin	17.03%
Free Cash Flow	$276.40M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.79
Inventory Turnover	5.03
Receiveable Turnover	5.24
Days Sales in Receivables	69.70
Return on Equity	18.37%
Return on Tangible Equity	19.20%
Return on Assets	13.52%
Return on Investments	17.08%
Book Value Per Share	$37.10
Free Cash Flow per Share	$3.75
Operating Cash Flow per Share	$8.87

Data from Zacks Investment Research, Inc.